Application of CDK4 / 6 inhibitors in the treatment of hormone receptor-positive breast cancer / 国际肿瘤学杂志

With roles of blocking cell proliferation,cyclin-dependent protein kinase (CDK)4 / 6 inhi-bitors are effective and safe complementary therapies for hormone receptor-positive breast cancer. CDK4 / 6 inhibitors combined with endocrine therapy significantly improve the prognosis of patients with advanced or metastatic breast cancer,especially those with endocrine resistance. Indications for CDK4 / 6 inhibitors are also expected to broaden into early-stage breast cancer. However,mechanisms of resistance of CDK4 / 6 inhibitors remain elusive.

Application of CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer / 国际肿瘤学杂志

With roles of blocking cell proliferation, cyclin-dependent protein kinase (CDK) 4/6 inhi-bitors are effective and safe complementary therapies for hormone receptor-positive breast cancer. CDK4/6 inhibitors combined with endocrine therapy significantly improve the prognosis of patients with advanced or metastatic breast cancer, especially those with endocrine resistance. Indications for CDK4/6 inhibitors are also expected to broaden into early-stage breast cancer. However, mechanisms of resistance of CDK4/6 inhibitors remain elusive.